Oculis Holding AG OCS 深 滬
等待開盤 07-06 09:30:00 美东时间
14.12
+0.590
+4.36%
華盛通- 最 高14.335
- 今 開13.72
- 成交量 39.84万股
- 最 低 13.55
- 昨 收 13.53
- 總市值 8.53亿
- 52周最高 34.475
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 10.52
- 委 比 0.00%
- 總股本 6038.81万
- 歷史最高 34.475
- 量 比 0.75
- 振 幅 5.80%
- 歷史最低 6.26
- 每 手 1
- 風險率 5.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference, where management will discuss its late-stage pipeline. Key highlights include Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, targeting a $7B+ market, and Licaminlimab, a topical anti-TNFα for dry eye disease. The Company is well-positioned to achieve value-driving milestones, f...
07-02 08:00
Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets the specific TNFR1
06-09 16:16
Oculis三期临床试验失败致股价暴跌，多家律所启动证券欺诈调查
生物制药公司Oculis Holding AG（纳斯达克代码：OCS）正面临多家股东权益律师事务所的证券欺诈调查。继2026年5月29日披露其核心候选药物...
06-09 03:47
Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky
Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema. NEW YORK, June 8, 202...
06-08 21:00
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Oculis Holding AG announced its participation in the 47th Annual Goldman Sachs Global Healthcare Conference, where its management will discuss its innovative pipeline. Key highlights include Privosegtor, a neuroprotective candidate with Breakthrough Therapy and PRIME designations for optic neuritis, targeting a $7B+ market in the U.S., and Licaminlimab, a topical anti-TNFα for dry eye disease as the first genotype-based precision medicine. With a...
06-08 18:45
股价暴跌！糖尿病黄斑水肿DME 3期失败，不计划NDA
药融圈数据监测显示：近期2026 年 5 月 29 日，总部位于瑞士楚格的全球生物制药公司 Oculis Holding AG（NASDAQ:OCS）公布其核心...
06-08 13:52
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
Why Is Oculis Stock Sinking Monday?
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.
06-01 22:12
